Amgen Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
Amgen Inc. (AMGN) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value of $20.14 billion as of 2018-03-31, per its 10-Q filed 2018-04-25.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue · last filed 2018-04-25
- 2018-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $20.14B.
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $25.25B.
- 2017-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $14.44B.
- 2017-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $14.42B.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value as first filed |
|---|---|---|
| 2018-03-31 | $20.14B 10-Q · filed 2018-04-25 | |
| 2017-12-31 | $25.25B 10-Q · filed 2018-04-25 | |
| 2017-09-30 | $14.44B 10-Q · filed 2017-10-26 | |
| 2017-06-30 | $14.42B 10-Q · filed 2017-07-26 | |
| 2017-03-31 | $14.83B 10-Q · filed 2017-04-27 | |
| 2016-12-31 | $18.28B 10-K · filed 2018-02-13 | |
| 2016-09-30 | $4.18B 10-Q · filed 2016-10-28 | |
| 2016-06-30 | $1.86B 10-Q · filed 2016-07-29 | |
| 2016-03-31 | $5.51B 10-Q · filed 2016-05-02 | |
| 2015-12-31 | $20.86B 10-K · filed 2017-02-14 | |
| 2015-09-30 | $9.14B 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $12.24B 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $5.00B 10-Q · filed 2015-04-27 | |
| 2014-12-31 | $11.64B 8-K · filed 2016-10-31 | |
| 2014-09-30 | $12.35B 10-Q · filed 2014-10-29 | |
| 2014-06-30 | $4.84B 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $8.90B 10-Q · filed 2014-04-30 | |
| 2013-12-31 | $9.42B 10-K · filed 2015-02-19 | $10.00B 10-K · filed 2014-02-24 |
| 2013-09-30 | $8.50B 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $10.70B 10-Q · filed 2013-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |